长药控股（300391）投资者索赔再提交法院立案，前期已有胜诉判决

Core Viewpoint - Long Pharmaceutical Holdings (长药控股) is facing legal actions due to allegations of false financial reporting and significant financial irregularities, with ongoing investor compensation claims being processed through the courts [1][3]. Group 1: Legal Proceedings - The law firm Shanghai Jucheng has submitted multiple claims to the Wuhan Intermediate People's Court on behalf of investors against Long Pharmaceutical Holdings, with previous successful cases serving as a precedent [1][3]. - The firm continues to accept claims from other investors who have suffered losses related to the company's stock [3]. Group 2: Financial Irregularities - Long Pharmaceutical Holdings announced on April 30, 2024, that it is under scrutiny for fund misappropriation and illegal guarantees, with an audit report highlighting significant uncertainties regarding its ongoing operations [4]. - The company reported a fund misappropriation amounting to 179,662,019.54 yuan, which represents 92.08% of its most recent audited net assets [4]. Group 3: Investor Compensation - Investors who purchased Long Pharmaceutical Holdings stock between March 30, 2019, and April 30, 2024, and sold or held their shares after April 30, 2024, are eligible to file for compensation based on previous successful judgments [5].